26
Sep
2024
Pfizer Withdraws Sickle Cell Drug, Arch Hauls in $3B, and BMS Wins Schizophrenia OK
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Sep
2024
Boundless Bio Takes on Oncogene Amplified Cancers: Zach Hornby on The Long Run
Zach Hornby is today’s guest on The Long Run. Zach is the CEO of San Diego-based Boundless Bio. The company is seeking to target cancer cells in an unusual way. It is developing small molecule drugs that take aim at DNA that resides outside the usual home on a chromosome. These oncogene amplifications occur in loops outside the chromosome. This... Read More